CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that Antony Blanc, PhD, was appointed Chief Business Officer and Chief Commercial Officer of CureVac. In this role, he will be responsible for building the network of partnerships that will support the growth of CureVac, for developing the competitiveness and commercial relevance of the company´s programs in development and for building the commercial organization.